
Upperton Pharma Solutions
Trent Gateway, Technology Drive, Beeston, Nottingham, NG9 1LA
UNITED KINGDOM
Visit Our Website
Visit Our Linkedin
Contact Us
Company Description
Upperton is a UK-based CDMO providing integrated contract development and manufacturing services. Specialising in oral, nasal, pulmonary and sterile dosage forms, Upperton offers a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical trial manufacture and commercial manufacture.
With over 25 years of experience, Upperton excels in rapid product introductions.
- Our project delivery is unparalleled and designed specifically to align with the
values and innovation of small to mid-sized pharma companies.
- We are flexible and nimble, enabling rapid decision-making, problem-solving, collaboration, and product introduction within 4-6 weeks.
- With subject matter experts and leadership team oversight on every project, you can trust our project delivery and expertise covers all layers of our operations.
- For small molecules and biologics, our clinical manufacturing process trains support batch sizes from grams to kilograms.
Integrated CDMO Services
Experts in Oral, Nasal, Pulmonary & Sterile Dosage Forms
Upperton offers expertise in developing a range of small molecule and biologics dosage forms, providing support from early feasibility studies through to clinical and commercial manufacture.
- Oral Solids: Upperton specialises in the development of both simple and complex oral dosage forms, including powders, capsules, and tablets (IR, MR, SR, Minitabs)
- Nasal: Supporting both liquid and dry powder formulation, the development platform, UpperNose™, streamlines and accelerates the process of developing nasal dosage forms for clinical trial studies.
- Pulmonary: Through expertise in formulation development, particle engineering and device selection. Upperton offers both dry powder and liquid formulation options, addressing factors such as solubility, stability, and target dose delivery into the lungs.
- Sterile: Our team can support you with aseptic and terminally sterilized small volume liquids and powders for parenteral, nasal and pulmonary delivery.
Our Manufacturing Capabilities at a Glance
- Up to 1,000,000 tableting capacity per day
- 500g – 205kg blending capacity
- Up to 2,000 blister packaging units per day
- Up to 50kg tablet coating per batch
- Up to 350,000 capsule filling (powder) capacity per day
- Up to 1000kg dry granulation capacity per day
- 0.5g – 10kg spray drying batch sizes (aqueous and solvent)
- 20 litres solution preparation vessels capacity with overhead mixing
- 10 state-of-the-art GMP manufacturing suites
Our Approach to Project Delivery
Upperton tailors projects to fit specific client timelines and requirements, prioritizing effective communication and collaboration in project delivery. Each project is assigned a project manager who coordinates all activities and ensures that transparency is maintained through regular updates.
Project teams at Upperton are composed of experts from various disciplines, including development, GMP, analytical, QA, and technical transfer. The inclusion of an Executive Leadership Team member in every project, ensures that decisions are made under expert guidance.
Upperton Pharma Solutions (Upperton) Wins Integrated Manufacturing Award at the 2025 Pharmaceutical Technology Excellence Awards.
- Upperton, UK-based CDMO (Contract, Development & Manufacturing Organization) recognized as winner in the Integrated Manufacturing (Business Expansion) category at the 2025 Pharmaceutical Technology Excellence Awards.
- Award follows the build of a 50,000 sq. ft development and manufacturing facility for oral, nasal and pulmonary dosage forms, alongside a 7,000 sq. ft sterile manufacturing facility built against revised EU GMP Annex-1 regulations.
- CEO, Nikki Whitfield said: “Being recognized as an Excellence Award winner is a great achievement and highlights the hard work of all of our team over the past few years. This award recognizes the vision we had when embarking on a new facility, and expansion into sterile manufacturing”.
Explore Our Resources
Videos
Discover Our Integrated CDMO Services
Whitepapers
Pharmaceutical Spray Drying: Technology & Applications
Transitioning Your Product from Phase 1 To Phase 2 Clinical Studies
Nose To Brain (N2B) Drug Delivery – Benefits & Challenges
Nasal Delivery of Spray Dried Biologics: Opportunities & Challenges
Spray Drying Biologics: An Alternative to Freeze Drying
In Vivo Testing of Nasal Dosage Forms
Interactive Facility Tour
Facility Tour
Interactive Brochures
With You from Pre-Clinical to Market
Your Sterile Partner of Choice
Webinars
Accelerating Nasal Dosage Form Development from Early-Phase to Clinical Trial Manufacture
Use Of Spray Drying in Pharmaceutical Product Development
Latest News
Upperton Pharma Solutions Awarded VaxHub Sustainable Grant to Advance Oral Vaccine Delivery in Partnership With the University of Oxford’s Pandemic Sciences Institute
Upperton named Champion Award winner at CDMO Leadership Awards 2025 in Small Molecule Dosage Form category.
Upperton completes build of new £7m sterile manufacturing facility
Upperton Pharma Solutions Adds Large-Scale Processing following MHRA Approval at Nottingham Facility
Posted Date: 4/17/2025
This record has been viewed 3914 times.